Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Anna ÅkerlundEmma JonassonErika MatuschekLena SerranderMartin SundqvistGunnar KahlmeterEsad DzajicDennis Schrøder HansenHarlotte Nielsen AgergaardAnu Pätäri-SampoRaija ManninenJuha GrönroosJean-Philippe RasigadeWaël SalkaPierre H. BoyerEvangelia LebessiNikolaos ZapaniotisEfi PetinakiIris SpiliopoulouFevronia KolonitsiouKristjan Orri HelgasonJean BrazilEleonora RiccobonoGiuliana Lo CascioLaura MaccacaroHelge KolstadTorunn Sneide HaukelandPirkko-Liisa KellokumpuAndreas Fossum MjøenStåle ToftelandBerit HarbakSusanne Hartvig HartzenSiri Haug HänsgenKarianne Wiger GammelsrudUnni SkolbekkenNina MichalsenAnita Løvås BrekkenBodil PedersenBrian GuennigsmanAstrid LiaAnn Kristin BergFrancesco MarcoCristina PitartPilar EgeaJose Luis Cortes-CuevasJesus MachucaMartin WietzkeMagdalena DammströmRoger GranströmMaria CorneliussonMarita SkarstedtKarin FrykfeldtCarina Lindqvist IvarssonAdam SergejevSusanna HagströmUlrika LidénJohan RydbergHanna RamströmInga FrödingEvangelos Alexandros PetropoulosKarolina IninbergsShah JalalAnna-Lena Sundqvist PerssonNina KamenskaKerstin GranlundAnna-Karin SmekalAnna HillGunilla RådbergGabriel HeymanLized RodriguezLisa VennbergGülşen HazırolanIsin AkyarGelmez Gülşen AltınkanatAyse Nur Sari KaygisizEsad DzajicDennis Schrøder HansenHarlotte Nielsen AgergaardAnu Pätäri-SampoRaija ManninenJuha GrönroosJean-Philippe RasigadeWaël SalkaPierre BoyerEvangelia LebessiNikolaos ZapaniotisEfi PetinakiIris SpiliopoulouFevronia KolonitsiouKristjan Orri HelgasonJean BrazilEleonora RiccobonoGiuliana Lo CascioLaura MaccacaroHelge KolstadTorunn Sneide HaukelandPirkko-Liisa KellokumpuAndreas Fossum MjøenStåle ToftelandBerit HarbakSusanne Hartvig HartzenSiri Haug HänsgenKarianne Wiger GammelsrudUnni SkolbekkenNina MichalsenAnita Løvås BrekkenBodil PedersenBrian GuennigsmanAstrid LiaAnn Kristin BergFrancesco MarcoCristina PitartPilar EgeaJose Luis Cortes-CuevasJesus MachucaMartin WietzkeMagdalena DammströmRoger GranströmMaria CorneliussonMarita SkarstedtKarin FrykfeldtCarina Lindqvist IvarssonAdam SergejevSusanna HagströmUlrika LidénJohan RydbergHanna RamströmInga FrödingEvangelos Alexandros PetropoulosKarolina IninbergsShah JalalAnna-Lena Sundqvist PerssonNina KamenskaKerstin GranlundAnna-Karin SmekalAnna HillGunilla RådbergGabriel HeymanLized RodriguezLisa VennbergGülşen HazırolanIsin AkyarGelmez Gülşen AltınkanatAyse Nur Sari Kaygisiz
• Organismes : Växjö Central Hospital Dept. of Clinical Microbiology Örebro University Växjö Central Hospital Institut des Agents Infectieux [Lyon] Pathogénie des Staphylocoques – Staphylococcal Pathogenesis [CIRI] Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Département de Microbiologie Clinique [HCL Groupement Hospitalier Nord, Lyon] Centre National de Référence Borréliose
• Publié dans Journal of Antimicrobial Chemotherapy le 31/10/2020

---

Résumé : Abstract Objectives When bloodstream infections are caused by resistant bacteria, rapid antimicrobial susceptibility testing (RAST) is important for adjustment of therapy. The EUCAST RAST method, directly from positive blood cultures, was validated in a multi-laboratory study in Europe. Methods RAST was performed in 40 laboratories in northern Europe (NE) and 15 in southern Europe (SE) from clinical blood cultures positive for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus or Streptococcus pneumoniae. Categorical results at 4, 6 and 8 h of incubation were compared with results for EUCAST standard 16–20 h disc diffusion. The method, preliminary breakpoints and the performance of the laboratories were evaluated. Results The total number of isolates was 833/318 in NE/SE. The number of zone diameters that could be read (88%, 96% and 99%) and interpreted (70%, 81% and 85%) increased with incubation time (4, 6 and 8 h). The categorical agreement was acceptable, with total error rates in NE/SE of 2.4%/4.9% at 4 h, 1.1%/3.5% at 6 h and 1.1%/3.3% at 8 h. False susceptibility at 4, 6 and 8 h of incubation was below 0.3% and 1.1% in NE and SE, respectively, and the corresponding percentages for false resistance were below 1.9% and 2.8%. After fine-tuning breakpoints, more zones could be interpreted (73%, 89% and 93%), with only marginally affected error rates. Conclusions The EUCAST RAST method can be implemented in routine laboratories without major investments. It provides reliable antimicrobial susceptibility testing results for relevant bloodstream infection pathogens after 4–6 h of incubation.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Alexandre DemouleMassimo AntonelliPeter SchellongowskiPeter PickkersMarcio SoaresTine MeyhoffJordi RelloPhilippe BauerAndry van de LouwVirgine LemialeDavid GrimaldiIgnacio Martin-LoechesMartin BalikSangeeta MehtaAchille KouatchetAndreas Barratt-DueMiia ValkonenJean ReignierVictoria MetaxaAnne-Sophie MoreauGaston BurghiDjamel MokartJulien MayauxMichaël DarmonÉlie AzoulayKarin AmreinPeter SchellongowskiThomas StaundingerGottfried HeinzGürkan SengölgeChristian ZaunerPeter JakschFabio TacconeDavid GrimaldiAnne Pascale MeertDominique BenoîtUlysses V.A. SilvaAna Paula Pierre de MoraesThiago LishoaMarcio SoaresJorge SalluhWilliam VianaGuilliana MoralezThiago Domingos CorreaSangeeta MehtaUmesh ShahThomas KarvunidisBalik MartinKaterina RussinovaAnders PernerTine Sylvest MeyhoffNielsen JonasRamin Brandt BukanAnn MoellerLene NielsenAchille KouatchetAmélie SeguinAkli ChermakNicolas TerziIsabelle VinatierAnne-Sophie MoreauFlorent WalletDjamel MokartKada KloucheLaura PlatonBenjamin GaboritFrançois BarbierFrederic PèneAntoine RabbatAlexandre DemouleJulien MayauxElie AzoulayVirginie LemialeMartine N'YungaChristophe GiraultCaroline LemaitreElise Artaud-MacariMichael DarmonF. BruneelAnne Sophie MoreauMiia ValkonenAnne KuitunenBrian MarshMater MisericordiaIgnacio Martin-LoechesAisling Mc MahonGilda CinnellaAntonella CotoiaOspedali RiunitiMassimo AntonelliLucas MontiniAngélique Spoelstra de ManPrecious Pearl LandburgDennis BergmansPeter PickkersPleun HemelaarThomas KaufmannAndreas Barrat-DuePål KlepstadJordi RelloBelen EncinaGabriel MorenoLlorenç Socias CrespiEmilio Rodriguez-RuizVictoria MetaxaGaston BurghiAndry van de LouwPhilippe BauerYadav Hemang
• Organismes : Sorbonne Université Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
• Publié dans Chest le 29/10/2020

---

Source

---

• Type de publi. : Ouvrage (y compris édition critique et traduction)
• Date de publi. : 01/11/2020
• Auteurs : Sylvie MaugatAnne Berger-CarbonneMélanie Colomb-CotinatPhilippe CavaliéCatherine DumartinMuriel PéfauEmmanuelle ReyreaudLory DugravotLoic SimonAmélie JouzeauC. MartinA. ChabaudAnne-Gaelle VenierBruno BarouxSonia JovelinJocelyne CaillonGabriel BirgandKarima Hyder-MlynarzIsabelle PelanneIsabelle ParentAlban DhananiAnne ChevanceNathalie JarrigeGéraldine CazeauGérard MoulinJean-Yves MadecRémi Pécault-CharbyA.S. LelongChristophe DagotMarie-Cécile PloySerge AlfandiariPhilippe LespritSolen KernéisPierre TattevinFrance RoblotEmmanuelle VaronRémi GauzitBernard CastanChristian RabaudP. VelgeCécile AdamCéline Coudert-ObertM. Le LoarerCéline PulciniM. BouqueauC. Godin-BenhaimAnne-Marie RoguesDidier LepelletierOlivia Keita-PersePierre ParneixBruno Grandbastien
• Organismes : Agence nationale du médicament vétérinaire Agence nationale du médicament vétérinaire

---

Résumé : La maîtrise de l'antibiorésistance repose en premier lieu sur la prévention des infections, en particulier des infections virales respiratoires. Ces dernières sont en effet l'objet de nombreuses prescriptions d'antibiotiques, soit par difficulté de diagnostic différentiel avec des infections bactériennes respiratoires, soit par crainte de complications par surinfections bactériennes.

---

Fichiers liés : 354748_spf00002585.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Elena PinchonFanny LeonNevzat TemurokFrançois MorvanJean-Jacques VasseurMartine ClotVincent FoulongneJean-François CantaloubePhilippe Van De PerreAurélien DaynèsJean-Pierre MolesChantal Fournier-Wirth
• Organismes : Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections HORIBA Medical Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] HORIBA Medical Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections HORIBA Medical Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections Pathogénèse et contrôle des infections chroniques (PCCI) Pathogenesis and Control of Chronic and Emerging Infections
• Publié dans Talanta le 01/11/2020

---

Résumé : The detection of DNA molecules by agglutination assays has suffered from a lack of specificity. The specificity can be improved by introducing a hybridization step with a specific probe. We developed a setting that captured biotinylated DNA targets between magnetic nanoparticles (MNPs) grafted with tetrathiolated probes and anti-biotin antibodies. The agglutination assay was enhanced using a series of magnetization cycles. This setting allowed to successfully detect a synthetic single stranded DNA with a sensitivity as low as 9 pM. We next adapted this setting to the detection of PCR products. We first developed an asymmetric pan-flavivirus amplification. Then, we demonstrated its ability to detect dengue virus with a limit of detection of 100 TCID 50 /mL. This magnetic field-enhanced agglutination assay is an endpoint readout, which benefits from the advantages of using nanoparticles that result in particular from a very reduced duration of the test; in our case it lasts less than 5 min. This approach provides a solution to develop new generation platforms for molecular diagnostics.

---

Fichiers liés : Talanta2020.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Guillaume GourcerolBenoit CoffinBruno BonazHélène HanaireStanislas Bruley. Des VarannesFrank ZerbibRobert CaiazzoJean Charles GrimaudFrançois MionSamy HadjadjPaul ValensiLucine VuittonGuillaume CharpentierAlain RopertRomain AltweggPhilippe PouderouxEtienne DorvalMichel DapoignyHenri DubocPierre-Yves BenhamouAurélie SchmidtNathalie DonnadieuPhilippe DucrotteBruno GuerciAnne Marie LeroiGaetan PrevostCaroline GorbatchefDaniela CalabreseFabian RecheNicolas MathieuFabienne VavasseurEric LetessierSébastien FontaineVincent MelkiIsabela BanuVéronique DesfourneauxAnne DuboisKarem Slim
• Organismes : Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau Institute for Research and Innovation in Biomedicine Centre d'Investigation Clinique [CHU Rouen] Service de Physiologie Digestive, Urinaire, Respiratoire et de l'Exercice [CHU Rouen] UNIROUEN - UFR Santé Hôpital Louis Mourier - AP-HP [Colombes] Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Régional Universitaire [CHU Lille] Recherche translationnelle sur le diabète - U 1190 Centre d'Investigation Clinique [Hôpital de la Conception - APHM] Centre Hospitalier Lyon Sud [CHU - HCL] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Jean Verdier [AP-HP] Centre Hospitalier Régional Universitaire de Besançon Laboratoire de Biologie de l'Exercice pour la Performance et la Santé Centre Hospitalier Sud Francilien Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] CHU Montpellier = Montpellier University Hospital Centre Hospitalier Universitaire de Nîmes CHU Trousseau [Tours] CHU Clermont-Ferrand Hôpital Louis Mourier - AP-HP [Colombes] Centre Hospitalier Universitaire [CHU Grenoble] STEVE CONSULTANTS 69600 OULLINS. Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau Institute for Research and Innovation in Biomedicine Centre d'Investigation Clinique [CHU Rouen] Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau Institute for Research and Innovation in Biomedicine Centre d'Investigation Clinique [CHU Rouen] Service d'Hépato-Gastroentérologie [CHU Rouen] UNIROUEN - UFR Santé Centre Hospitalier Universitaire de Nancy Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group Enterra Research Group
• Publié dans Clinical Gastroenterology and Hepatology le 30/10/2020

---

Résumé : Background & Aims. Medico-economic data of patients suffering from chronic nausea and vomiting are lacking. In these patients, gastric electrical stimulation (GES) is an effective, but costly treatment. The aim of this study was to assess the efficacy, safety and medico-economic impact of Enterra therapy in patients with chronic medically refractory nausea and vomiting. Methods. Data were collected prospectively from patients with medically refractory nausea and/or vomiting, implanted with an Enterra device and followed for two years. Gastrointestinal quality of life index (GIQLI) score, vomiting frequency, nutritional status and safety were evaluated. Direct and indirect expenditure data were prospectively collected in diaries. Results. Complete clinical data were available for142 patients (60 diabetic, 82 non-diabetic) and medico-economic data were available for 96 patients (36 diabetic, 60 non-diabetic), 24 months after implantation. GIQLI score increased by 12.1 ± 25.0 points (p < .001), with a more significant improvement in non-diabetic than in diabetic patients (+15.8 ± 25.0 points, p < .001 versus 7.3 ± 24.5 points, p = .027, respectively). The proportion of patients vomiting less than once per month increased by 25.5% (p < .001). Hospitalisations, time off work and transport were the main sources of costs. Enterra therapy decreased mean overall healthcare costs from 8873 US$ to 5525 US$ /patient/year (p = .001), representing a saving of 3348 US$ per patient and per year. Savings were greater for diabetic patients (4096 US$ /patient/year) than for non-diabetic patients (2900 US$ /patient/year). Conclusions. Enterra therapy is an effective, safe and cost-effective option for patients with refractory nausea and vomiting. ClinicalTrials.gov Identifier: NCT00903799

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Florence RougetPhilippe KadhelChristine MonfortJ.-F. VielJean Pierre ThomeSylvaine CordierLuc Multigner
• Organismes : Institut de recherche en santé, environnement et travail École des Hautes Études en Santé Publique École des Hautes Études en Santé Publique Institut de recherche en santé, environnement et travail Institut de recherche en santé, environnement et travail École des Hautes Études en Santé Publique Institut de recherche en santé, environnement et travail École des Hautes Études en Santé Publique Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich École des Hautes Études en Santé Publique Institut de recherche en santé, environnement et travail Institut de recherche en santé, environnement et travail École des Hautes Études en Santé Publique
• Publié dans Environmental Science and Pollution Research le 22/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Paul GuedeneyMohamad El KastyMikael LaredoRaphaëlle DumaineGrégory DucrocqÉric VicautJohanne SilvainJean-Philippe ColletGilles MontalescotMathieu KerneïsNassim BraikOlivier BarthelemyGérard HelftClaude LefeuvreRémi ChoussatMarie HauguelMichel ZeitouniThomas CuissetJean Louis BonnetPierre DeharoBenoît LattucaGuillaume CaylaLuc CornilletBertrand LedermannClément LonjonLaurent SchmutzGrégoire RangéFranck AlbertThibault DemicheliLaurent RousselReda BensaidChristophe ThuaireJean-Guillaume DillingerPatrick HenryStéphane Manzo-SilbermanGeorgios SiderisDamien LogeartVincent SpagnoliChristophe PouillotJean Richard Vi-FaneJens GlasenappKarim BougriniNicolas CombaretPascal MotreffGéraud SouteyrandAimé AmonchotThomas MouyenThibault LhermusierDidier CarrieFrédéric BouissetThomas CholletFrancisco Campelo-ParadaNicolas DelarcheFrançois SchieleMathieu BesuttiMarie Hauguel-MoreauChristophe CaussinMami ZoheirAurelie VeugeoisAlain DibieOlivier VarenneFabien PicardAlexandre LafontJulien AdjedjPhilippe DegrellFarzin BeyguiRémi SabatierVincent RouleMathieux BignonKatrien BlanchartPierre ArdouinAdrien LemaitreClément BrietZiad BoueriPascal GoubePierre CosteLaura CetranJérôme ClercHervé Le BretonDominique BoulmierVincent AuffretJean-Noël LabequeJean-Luc BonasJean-Louis GeorgesBernard LivarekElodie BlicqNicolas BaronGéraldine Gibault-GentyYves CottinIsabelle LhuillierCarole RichardLuc LorgisPhilippe BuffetChristian SpauldingNicole KaramÉtienne PuymiratMarco MennuniEmmanuel PoulidakisLionel BonnevieFranck BoccaraMarion ChauvetLaurie DufourYann AncedyStéphane EderhyArnaud EtienneyAnne Bellemain-AppaixNathaniel BittonLaurent JacqChristophe Saint-EtienneFlorence LeclercqFrançois RoubilleGilles RioufolFrançois DerimayMarc GoralskiWael YafiEmmanuelle FilippiAlain KermarrecChristophe Le RayAntoine MerletAurelie LoiratPhilippe BrunelDamien BrunetJack RavisyLaurent MockGuillaume MolinsErwan BressolletteLuc ChristiaensElisa Larrieu-ArdilouzeRomain Cador CadorEric van BelleGilles LemesleCédric DelhayeFlavien VincentSina PorouchaniHugues SpillemaekerKaty PetitOlivier RessencourtMax CarreVincent HumeauFrançois JourdaMarc-Antoine ArnouldStephen ChassaingKarl IsaazLaurent PayotJacques MontseguBenjamin FaurieMichel PansieriMarc MetgeKarim MoussaMathieu PankertOlivier MorelSébastien L G HessLuc MaillardThibault ManigoldVincent LetocartJulien PlessisPauline BerthomeMickael BoninEmmanuel TeigerRomain GalletGauthier MouilletMadjid BoukantarRami El MahmoudMohammed NejjariDavid AttiasLéa CacoubMathieu SteineckerFrançois HuchetZuzana MotovskaMartin KozelZdenko StelmachOta HlinomazMichal RezekMartin NovakJan SitarJiri SemenkaPetr KalaOtakar BocekRoman ŠtipalMartin PoloczekJan KanovskýPetr JerabekJiří KarasekSylvie HruskovaMarian BrannyJan MrozekTomas GrezlLeos PlevaPavel KuklaMartin Porzer
• Organismes : Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011
• Publié dans The Lancet le 02/11/2020

---

Fichiers liés : 2020 Silvain et al., Ticagrelor versus.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Ronan TréposLuc ChampolivierJean-François DejouxAhmad Al BitarPierre CasadebaigPhilippe Debaeke
• Organismes : Unité de Mathématiques et Informatique Appliquées de Toulouse Terres Inovia Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère AGroécologie, Innovations, teRritoires AGroécologie, Innovations, teRritoires
• Publié dans Remote Sensing le 28/10/2020

---

Résumé : Forecasting sunflower grain yield a few weeks before crop harvesting is of strategic interest for cooperatives that collect and store grains. With such information, they can optimize their logistics and thus reduce the financial and environmental costs of grain storage. To provide these predictions, data assimilation approaches involving the crop model SUNFLO are used. The methods are based on the re-estimation of soil conditions and on the sequential update of crop model states using an ensemble Kalman filter. They combine the simulation of the crop model and time series of leaf area index (LAI) derived from remote sensors and extracted over 281 fields near Toulouse, France. A sensitivity analysis is used to identify the most relevant model inputs to consider into the data assimilation process. Results show that data assimilation leads to statistically significant better predictions than the simulation alone (from an RMSE of 9.88 q.ha(-1) to an RMSE 7.49 q.ha(-1)). Significant improvement is achieved by relying on smoothed LAI rather than raw LAI. Nevertheless, there is still an over estimation of the grain yield that can be partially explained by the limiting factors observed on the fields and the forecast yield still need improvements to meet the required applications' accuracy.

---

Fichiers liés : remotesensing-12-03816-v3.pdf

---

Source

---

• Type de publi. : Rapport
• Date de publi. : 01/11/2020
• Auteurs : Pierre PapinMatthieu GaultierJulien AngladeJessie DuvalPhilippe GardèreChristophe LebrunJean SoulatAlexandre VialeMurielle Troubady
• Organismes : Service de l'archéologie du département d'Indre-et-Loire Cités, Territoires, Environnement et Sociétés Service de l'archéologie du département d'Indre-et-Loire Service de l'archéologie du département d'Indre-et-Loire Cités, Territoires, Environnement et Sociétés Institut national de recherches archéologiques préventives Service de l'archéologie du département d'Indre-et-Loire LandArc Service de l'archéologie du département d'Indre-et-Loire Service de l'archéologie du département d'Indre-et-Loire

---

Fichiers liés : LPV20_Rapport.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Benoit CoudertJean-Yves PiergaMarie-Ange Mouret-ReynierKaldoun KerrouJean-Marc FerreroThierry PetitFanny Le DuPierre-François DupréThomas BachelotPhilippe GabelleMarie-Pierre ChauvetDavid CoefficCatherine BarbeJean-Briac PrevostGilles PaintaudGilles ThibaultAbdennour FerhatJulien DupinAlina Berriolo-RiedingerLaurent Arnould
• Organismes : Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] Institut Curie [Paris] Centre Jean Perrin [Clermont-Ferrand] CHU Tenon [AP-HP] Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] Centre Paul Strauss CRLCC Eugène Marquis Hôpital Morvan - CHRU de Brest Centre Léon Bérard [Lyon] Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Hôpital Bretonneau Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Roche France Roche France Département d'information médicale [Centre Georges-François Leclerc] Département d'information médicale [Centre Georges-François Leclerc]
• Publié dans EClinicalMedicine le 01/11/2020

---

Résumé : Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes. Methods: Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomised (2:1) to neoadjuvant therapy with (Group A) or without (Group B) bevacizumab for cycles 3-6. All patients received one further cycle of trastuzumab before surgery plus adjuvant trastuzumab (11 cycles). Findings: 142 patients were randomized and treated (PET responders, n = 69; Group A, n = 48; Group B, n = 25). 5-year disease-free survival rates were 90.5% (95% CI: 80.0-95.6%) in PET responders, 90.2% (95% CI: 75.9-96.2%) in Group A, and 76.0% (95% CI: 54.2-88.4%) in Group B. However, no difference was observed between randomised arms in a sensitivity analysis. During adjuvant therapy, the incidence of Grade ≥3 (Group A: 25.6%; Group B 12.5%) and serious adverse events (Group A: 18.6%; Group B 12.5%) was higher in Group A vs Group B, but with no apparent effect on cardiac events. Interpretation: In patients with HER2-positive breast cancer, an intervention based on early PET assessment and improvement of pCR does not modify disease-free survival.

---

Fichiers liés : PIIS2589537020303102.pdf

---

Source